1 week Ago By ABMN Staff
Vertex Pharmaceuticals Incorporated ( NASDAQ:VRTX – Get Free Report ) has been assigned a consensus rating of “Moderate Buy” from the thirty-one brokerages that are currently covering the firm, MarketBeat reports. Three analysts have rated the stock with a sell recommendation, ten have assigned a hold recommendation, seventeen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $494.
04. A number of brokerages recently issued reports on VRTX. Stifel Nicolaus increased their target price on shares of Vertex Pharmaceuticals from $490.
00 to $494.00 and gave the stock a “hold” rating in a research report on Monday, December 16th. Scotiabank increased their target price on Vertex Pharmaceuticals from $426.
00 to $430.00 and gave the stock a “sector perform” rating in a report on Monday, December 23rd. UBS Group upped their price target on shares of Vertex Pharmaceuticals from $562.
00 to $586.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Royal Bank of Canada raised their price objective on shares of Vertex Pharmaceuticals from $437.
00 to $451.00 and gave the company a “sector perform” rating in a research report on Tuesday, November 5th. Finally, Jefferies Financial Group upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and upped their target price for the stock from $500.
00 to $550.00 in a research report on Monday, December 9th. Check Out Our Latest Stock Report on Vertex Pharmaceuticals Vertex Pharmaceuticals Trading Up 0.
3 % Vertex Pharmaceuticals ( NASDAQ:VRTX – Get Free Report ) last released its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, beating analysts’ consensus estimates of $3.
61 by $0.77. The company had revenue of $2.
77 billion for the quarter, compared to the consensus estimate of $2.69 billion. Vertex Pharmaceuticals had a negative return on equity of 1.
91% and a negative net margin of 4.52%. The company’s quarterly revenue was up 11.
6% on a year-over-year basis. During the same period in the previous year, the business earned $3.67 earnings per share.
On average, equities research analysts forecast that Vertex Pharmaceuticals will post -1.83 earnings per share for the current fiscal year. Institutional Inflows and Outflows Hedge funds and other institutional investors have recently modified their holdings of the company.
Northwest Investment Counselors LLC acquired a new stake in shares of Vertex Pharmaceuticals in the third quarter valued at approximately $25,000. Dunhill Financial LLC increased its holdings in shares of Vertex Pharmaceuticals by 70.6% in the third quarter.
Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 24 shares during the last quarter. Highline Wealth Partners LLC bought a new position in shares of Vertex Pharmaceuticals in the third quarter valued at about $27,000. GHP Investment Advisors Inc.
acquired a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter worth about $29,000. Finally, Legacy Investment Solutions LLC bought a new stake in shares of Vertex Pharmaceuticals during the 3rd quarter worth about $33,000. Institutional investors own 90.
96% of the company’s stock. Vertex Pharmaceuticals Company Profile ( Get Free Report Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Recommended Stories Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter ..
